5 research outputs found

    MOESM1 of Selection, characterization, and thermal stabilization of llama single domain antibodies towards Ebola virus glycoprotein

    No full text
    Additional file 1: Figure S1. Biopanning against EBOV GP. The titer of eluted phage was determined at the end of each round of biopanning. Figure S2. Thirty-four potential GP-binding sdAb sequences selected from the second and third rounds of panning against EBOV GP. Sequences were divided into families based on similarity of CDR sequences. Figure S3. Representative measurements of binding kinetics and KD using SPR biosensor. Figure S4. Table of IMGT number and corresponding amino acid at each position for clones EBOV-GP-A8, EBOV-GP–H7 and EBOV-GP-G6. Figure S5. Competition data assessing the ability of the sdAbs to bind GP that was pre-bound with EBOV-GP-A8. Figure S6. Western blotting analysis of GP and VLP binding specificity and cross reactivity for EBOV-GP-G6-neg+-GSKKK

    MOESM3 of Enhanced production of a single domain antibody with an engineered stabilizing extra disulfide bond

    No full text
    Additional file 3: Figure S3. Sequence alignment of sdAb AC and variants. Sequence alignment of the SEB binding sdAb AC, AC+, AC+neg and AC+neg2 using MultAlin [29]. The initial two amino acids (MA) and the amino acids added due to the restriction sites and the His-tag are not show above (AAALEHHHHHH)

    MOESM4 of Enhanced production of a single domain antibody with an engineered stabilizing extra disulfide bond

    No full text
    Additional file 4: Figure S4. Molecular weight and purity assessment of sdAb. Figure S4. Assessment of purity for purified single domain antibodies on gel electrophoresis. The virtual gel was obtained from Experion Pro260 chip (Bio-Rad laboratories). Approximately 200 µg/mL for each protein sample was used. The peak density of purified single domain antibodies as indicated by the blue arrow is >95 %. The rest of the bands represent high and low markers and internal systematic bands as indicated by the magenta arrows and described as such in the manufacturer’s protocol (Bio-Rad). Sample order is as follows, Lane L: Molecular marker Ladder. L1: ACneg; L2: AC+neg; L3: AC+neg2; L4: AC+;L5: A3+; L6: A3+neg; L7: G2+; L8: G2+neg; L9: G2+neg2; L10: G2
    corecore